Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ophthotech Corp (NASDAQ:OPHT)

64.24
Delayed Data
As of Jul 29
 -0.79 / -1.21%
Today’s Change
35.72
Today|||52-Week Range
80.00
-18.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.3B

Company Description

Ophthotech Corp. operates as a biopharmaceutical company. It focuses on discovering, developing and commercializing novel therapeutics to treat diseases of the back of the eye. It develops therapies for age-related macular degeneration. Its product candidates include Fovista Anti platelet derived growth factor Therapy, Zimura Anti-Complement and Aptamer Technology. The company was founded on January 5, 2007 by David R. Guyer and Samir Chandrakant Patel and is headquartered in New York, NY.

Contact Information

Ophthotech Corp.
One Penn Plaza
New York New York 10119
P:(212) 845-8200
Investor Relations:
(212) 845-8231

Employees

Shareholders

Mutual fund holders45.47%
Individual stakeholders37.25%
Other institutional33.45%

Top Executives

David R. GuyerChairman & Chief Executive Officer
Samir Chandrakant PatelPresident & Vice Chairman
Glenn P. SblendorioTreasurer, Chief Financial & Operating Officer
Harvey N. MasonsonSenior Vice President-Clinical Development
Henric BjarkeChief Commercial Officer & Senior Vice President